Evidence check: CYP2D6 in the context of Allergie

CYP2D6 is a key drug-metabolizing enzyme involved in the breakdown of many medications, including some antihistamines and other allergy drugs. However, the provided context contains no specific studies or data linking CYP2D6 variants directly to allergy risk or severity. The evidence level is therefore mechanistic/unclear: plausible biochemical pathways exist (e.g., altered metabolism of anti-allergy drugs), but no robust human studies confirm a clinically relevant association with allergy phenotypes. DTC genetic tests marketing CYP2D6 in the allergy context often overstate its significance. A DNA test cannot replace allergy diagnosis or management; blood levels and physician oversight are essential. Safety note: CYP2D6 phenotypes (poor, intermediate, extensive, ultrarapid metabolizer) can affect efficacy and side effects of allergy medications – this should be addressed through clinical pharmacogenetic counseling, not via direct-to-consumer testing.